ALNA (Allena Pharmaceuticals) NASDAQ pre-market $0.08 Feb 20, 2026: heavy volume

ALNA stock is trading in the pre-market on NASDAQ at $0.075, up 3.16% from yesterday, with a heavy reported volume of 252,311,606 shares. Investors are watching Allena Pharmaceuticals, Inc. (ALNA) for news on its lead enzyme program ALLN-346 and near-term funding signals. This pre-market move follows yesterday’s open at $0.0641 and a previous close of $0.0727, and it sets the stage for active trading in the United States healthcare small-cap biotech space.

ALNA stock pre-market price and trading activity

ALNA stock opened pre-market at $0.0641 and is quoted at $0.075 as of this update. The 1-day change is $0.00230 or 3.16%, with a day low of $0.06 and a day high of $0.14590. Reported volume of 252,311,606 shares signals unusually high activity for a micro-cap biotech on NASDAQ in the United States. High volume often reflects headline risk or share supply shifts and can increase short-term volatility for ALNA stock.

ALNA stock fundamentals and key metrics

Allena Pharmaceuticals operates in the Healthcare sector and Biotechnology industry. The company shows EPS of -0.64 and a negative P/E near -0.12, reflecting pre-revenue biotech status. Balance-sheet metrics include cash per share $0.92 and book value per share $0.58, with a current ratio of 2.11, indicating liquidity to fund operations short term. Enterprise value is listed negative in source data due to small market capitalization and cash balances. These metrics show structural burn and clinical-stage risk in ALNA stock.

ALNA stock catalysts, pipeline and news flow

The primary clinical catalyst for Allena Pharmaceuticals is ALLN-346, an oral urate-degrading enzyme candidate for patients with hyperuricemia and gout in advanced chronic kidney disease. Near-term catalysts that could move ALNA stock include clinical updates, regulatory interactions, or financing announcements. With no recent public earnings beat or new guidance, trading swings are likely driven by micro-cap flows and speculative positioning rather than fresh fundamental news.

ALNA stock valuation and technical context

Valuation ratios are atypical because ALNA is pre-commercial. Price-to-book is 0.13 while price-to-sales is effectively 0.00 given minimal revenue. Technicals show a wide intraday range (low $0.06, high $0.14590) and volume concentration, which favors active trading strategies rather than long-term value plays. For traders, tight stop sizing and liquidity checks are essential because implied bid-ask spread and volume may move quickly for ALNA stock.

ALNA stock Meyka AI grade and forecast

Meyka AI rates ALNA with a score of 62.44 out of 100 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a base-case price target of $0.12, a bull-case of $0.25, and a bear-case of $0.04, compared with the current price of USD 0.075. That implies a base-case upside of 60.00%, a bull upside of 233.33%, and a bear downside of -46.67%. Forecasts are model-based projections and not guarantees.

ALNA stock risks and investor considerations

ALNA stock carries typical clinical-stage biotech risks: clinical failure, regulatory setbacks, and dilution through financing. Cash runway and financing terms will materially affect shareholder value. Operational metrics such as negative operating cash flow per share -1.41 and negative net income per share -1.03 highlight ongoing cash burn. Investors should weigh sector dynamics in Healthcare and Biotech and use position sizing that reflects high volatility in ALNA stock.

Final Thoughts

Key takeaways: ALNA stock is actively trading in the NASDAQ pre-market at $0.075 with heavy volume of 252,311,606 shares, driven by micro-cap flows and ongoing interest in Allena’s ALLN-346 program. Fundamentals show cash per share $0.92, EPS -0.64, and a current ratio 2.11, indicating liquidity but continued burn. Meyka AI rates ALNA 62.44/100 (B, HOLD) and issues a model-based base-case price target of $0.12 (implied 60.00% upside from USD 0.075). We outline a bull target $0.25 and a bear target $0.04 to frame risk-reward for traders and investors. Given the clinical-stage profile and elevated intraday volatility, active traders may find short-term opportunities while longer-term investors should wait for clinical or financing clarity. This snapshot is part of our AI-powered market analysis; always cross-check company filings and official announcements before making decisions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.